Mayne Pharma Posts Strong Cash Flow and Momentum in Women’s Health on 3Q FY26 Update

Mayne Pharma Group ( (AU:MYX) ) has shared an announcement.

Mayne Pharma reported unaudited third-quarter FY26 revenue of A$85.2 million, up 1% year on year, with gross margin expanding to 63% and underlying EBITDA narrowing to a A$1.4 million loss. Adjusted operating cash flow from continuing operations surged 90% to A$28.3 million, lifting cash and marketable securities to A$86.7 million and giving the company greater flexibility to reinvest in growth priorities and selective business development.

Operationally, the March launch of DistributeRx significantly outperformed internal and prior-period prescription volumes, while women’s health brands BIJUVA and NEXTSTELLIS delivered strong demand growth supported by refreshed marketing and field execution. An FDA update to hormone therapy labelling removed key warnings for BIJUVA, which, together with solid dermatology contribution and minimal impact from recent U.S. tariffs, positions Mayne Pharma with improving commercial momentum into the fourth quarter despite a temporary BIJUVA supply disruption.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma Group, listed on the ASX, operates in the specialty pharmaceuticals industry with a strong focus on the U.S. market. Its primary products span women’s health therapies, including contraception and menopause treatments such as NEXTSTELLIS, ANNOVERA, IMVEXXY and BIJUVA, alongside a dermatology portfolio and new distribution initiatives like DistributeRx.

Average Trading Volume: 466,107

Technical Sentiment Signal: Sell

Current Market Cap: A$208.8M

For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.